These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 32504568)

  • 1. Weighing considerations with newer antiretrovirals.
    Venter WDF; Hill A
    Lancet HIV; 2020 Jun; 7(6):e374-e375. PubMed ID: 32504568
    [No Abstract]   [Full Text] [Related]  

  • 2. Bictegravir and dolutegravir: head to head at 96 weeks.
    Barber TJ
    Lancet HIV; 2019 Jun; 6(6):e342-e343. PubMed ID: 31068271
    [No Abstract]   [Full Text] [Related]  

  • 3. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bictegravir.
    Spagnuolo V; Castagna A; Lazzarin A
    Curr Opin HIV AIDS; 2018 Jul; 13(4):326-333. PubMed ID: 29746268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First pharmacokinetic data of bictegravir in pregnant women living with HIV.
    Bukkems VE; Hidalgo-Tenorio C; Garcia C; van Hulzen AGW; Richel O; Burger DM; Colbers AP;
    AIDS; 2021 Nov; 35(14):2405-2406. PubMed ID: 34723856
    [No Abstract]   [Full Text] [Related]  

  • 12. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
    J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
    Gelé T; Gouget H; Furlan V; Becker PH; Taburet AM; Lambotte O; Barrail-Tran A
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
    Taiwo BO; Quiñones-Mateu ME; Smith K; Zheng L; Gulick R; Nyaku AN; Sax PE; Ha B; Kumwenda J; Olefsky M; Godfrey C; Wallis C
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):254-255. PubMed ID: 31914799
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV 101: fundamentals of antiretroviral therapy.
    Saag MS
    Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
    Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
    S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
    Fulco PP; Leibrand Kaczmar CR; Gomes D; Smith T
    J Clin Pharm Ther; 2020 Apr; 45(2):394-396. PubMed ID: 31765502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Maartens G; Boffito M; Flexner CW
    Curr Opin HIV AIDS; 2017 Jul; 12(4):355-358. PubMed ID: 28403028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.
    Zhang WW; Cheung PK; Oliveira N; Robbins MA; Harrigan PR; Shahid A
    J Infect Dis; 2018 Oct; 218(11):1773-1776. PubMed ID: 30010985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.